Project Grant R01HL176337
Award Date
9/5/24
Completion Date
6/30/29
Dollars Obligated
$647K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06510, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,251,718 to the University of California, Los Angeles (UCLA) to conduct a longitudinal cohort study called "Heart and Lung Outcomes Post-TB (HALO POST-TB)". The study aims to elucidate the prevalence, trajectory, and mechanisms of cardiopulmonary abnormalities after tuberculosis (TB), and the role of HIV as an effect modifier,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,321,108 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to New York University School of Medicine to conduct transdisciplinary implementation research on a strategy called PT4A. PT4A integrates peer-based medication delivery, peer coaching, and health information technology to improve medication adherence and reduce blood pressure among patients with uncontrolled hypertension in Western Kenya. The study aims to...
This Project Grant award of $162,820 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to develop a community-clinical linkage model to facilitate referral of people living with HIV (PLWH) and comorbid hypertension to primary healthcare centers in Akwa Ibom, Nigeria. The research aims are to: 1) identify barriers and facilitators to this model, 2) co-develop a culturally-tailored,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the burden, severity, and phenotypic presentation of post-tuberculosis (TB) lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in TB patients with and without HIV. The total funding amount is $743,698.00 over the award period from Sep 20, 2024 to Aug 31, 2029. The grant will leverage an...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to identify and adapt an intervention to address common mental disorders (CMDs) among people being treated for tuberculosis (TB) in Uganda. The total award amount is $134,811 over a 5-year period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) examine the relationship between CMDs and TB...
This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize metabolic profiles and outcomes among tuberculosis (TB) patients in Tanzania. The $201,549 award to the Medical University of South Carolina will fund a 5-year study with the following objectives: Measure and describe metabolic markers and TB severity at the time of TB diagnosis, testing...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $1,415,374 to the University of Washington to evaluate the integration of HIV prevention, including HIV self-testing and pre-exposure prophylaxis (PrEP), into household-based tuberculosis (TB) contact investigation in Uganda. The overarching goals are to assess the implementation, effectiveness, and cost-effectiveness of this integrated approach to...
This $565,250 federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a 5-year longitudinal study led by Duke University to characterize the effects of host-microbiome interactions on pulmonary function in a cohort of 500 adults with and without HIV in Botswana. The study will utilize advanced multi-omics techniques, including shotgun metagenomic sequencing, host...
This federal Project Grant award of $116,748.00, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to enhance the recipient's capability as a leader in patient-oriented cardiovascular research and mentorship at Washington University. The key products and services to be delivered under this grant include: 1) Conducting new advanced implementation research using the NHLBI-funded Hypertension Treatment in Nigeria...